淋系与髓系克隆性造血的区分
研究在UK Biobank和Mass General Brigham Biobank中分析55,383例个体的CHIP和420,969例个体的常染色体mCAs,区分髓系与淋系体细胞突变及mCAs,发现二者分别与谱系特异性血液恶性肿瘤风险相关,整合血细胞计数参数可分层风险。
要点
- 髓系与淋系体细胞突变及mCAs分别与谱系特异性血液恶性肿瘤风险相关
- 整合体细胞变异与血细胞计数参数可分层髓系和淋系恶性肿瘤发生风险
- 这些遗传变异可在临床测序面板中检测,联合血细胞计数识别高危个体
核心结论
- 髓系和淋系体细胞突变及mCAs分别与谱系特异性血液恶性肿瘤风险相关,整合血细胞计数可分层风险。
研究设计与样本
- 在UK Biobank和Mass General Brigham Biobank中分析55,383例无血液恶性肿瘤史个体的CHIP和420,969例个体的常染色体mCAs。
主要发现
- 区分髓系与淋系体细胞基因突变及髓系与淋系mCAs后,二者均与谱系特异性血液恶性肿瘤风险相关。
- 整合体细胞变异与外周血细胞计数参数可分层髓系和淋系恶性肿瘤发生风险。
临床怎么用
- 这些遗传变异可在临床测序面板中检测,联合血细胞计数参数识别血液恶性肿瘤高危个体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clonal hematopoiesis (CH) results from somatic genomic alterations that drive clonal expansion of blood cells. Somatic gene mutations associated with hematologic malignancies detected in hematopoietic cells of healthy individuals, referred to as CH of indeterminate potential (CHIP), have been associated with myeloid malignancies, while mosaic chromosomal alterations (mCAs) have been associated with lymphoid malignancies. Here, we analyzed CHIP in 55,383 individuals and autosomal mCAs in 420,969 individuals with no history of hematologic malignancies in the UK Biobank and Mass General Brigham Biobank. We distinguished myeloid and lymphoid somatic gene mutations, as well as myeloid and lymphoid mCAs, and found both to be associated with risk of lineage-specific hematologic malignancies. Further, we performed an integrated analysis of somatic alterations with peripheral blood count parameters to stratify the risk of incident myeloid and lymphoid malignancies. These genetic alterations can be readily detected in clinical sequencing panels and used with blood count parameters to identify individuals at high risk of developing hematologic malignancies.
引用
- Niroula A, Sekar A, Murakami MA, et al. Distinction of lymphoid and myeloid clonal hematopoiesis. Nat Med. 2021. PMID: 34663986. doi:10.1038/s41591-021-01521-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。